Skip to main content
. 2022 Dec 13;13:7711. doi: 10.1038/s41467-022-35480-2

Fig. 4. Cumulative incidence and vaccine efficacy against infection and substantial symptomatic disease.

Fig. 4

Cumulative incidence of a all SARS-CoV-2 infections among the mRNA1273 fourth dose arm and their matched controls, b all SARS-CoV-2 infections among the BNT162b2 fourth dose arm and their matched controls, c substantial symptomatic disease among the mRNA1273 fourth dose arm and their matched controls, and d substantial symptomatic disease among the BNT162b2 fourth dose arm and their matched controls. Vaccine efficacy against infection (for mRNA1273: n = 115, for BNT162b2: n = 150) and substantial symptomatic disease (for mRNA1273: n = 115, for BNT162b2: n = 147) for both vaccines compared to receiving three vaccine doses, estimated using an adjusted Poisson regression, is demonstrated in plot (e). In each figure, the outcome is presented using a 95% confidence interval. Source data are provided as a Source Data file.